Kelun-Biotech is advancing 30+ oncology candidates through clinical trials, positioning the Chinese biotech as a major competitor in the accelerating antibody-drug conjugate (ADC) market.1 The expanded pipeline coincides with concentrated regulatory milestones from 2026-2029, creating a competitive approval cycle for cancer therapies.
BioNTech presented clinical data at ELCC 2026 for pumitamig, gotistobart, and a HER3-targeted ADC across lung cancer settings.2 "We continue to advance differentiated treatment approaches across lung cancer settings while building the clinical evidence to guide their further development," said Prof. Özlem Türeci, BioNTech's Chief Medical Officer.2
Regeneron secured Japanese approval for Dupixent in bullous pemphigoid, expanding the IL-4/IL-13 pathway inhibitor beyond previous indications.3 The fully human monoclonal antibody represents Regeneron's push into dermatological conditions with targeted immunology.
Silexion Therapeutics received Israeli Ministry of Health approval for a Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer, where KRAS mutations appear in over 90% of cases.4 The trial follows positive Phase 2a results for predecessor drug Loder versus chemotherapy alone.4
The convergence of late-stage oncology programs from Chinese biotechs and Western pharma creates near-term catalysts for healthcare investors. ADC platforms target specific tumor antigens while minimizing systemic toxicity, addressing a key limitation of traditional chemotherapy.
Ascentage Pharma and Terns Pharmaceuticals also advanced oncology programs through regulatory processes in March 2026, though specific trial data was not disclosed.5 The cluster of activity from 2026-2027 suggests overlapping approval timelines that will determine market share across cancer subtypes.
For market-focused investors, the oncology pipeline acceleration presents sector rotation opportunities as trial readouts and regulatory decisions drive volatility in individual biotech names through 2027.
